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Abstract
Background: Although radiotherapy following mastectomy was demonstrated to reduce the recurring risk and
improve the prognosis of patients with breast cancer, it is also notorious for comprehensive side effects, hence only
a selected group of patients can benefit. Therefore, the screening of molecular markers capable of predicting the
efficacy of radiotherapy is essential.
Methods: We have established a cohort of 454 breast cancer cases and selected 238 patients with indications for
postoperative radiotherapy. Synuclein-γ (SNCG) protein levels were assessed by immunohistochemistry, and SNCG
status was retrospectively correlated with clinical features and survival in patients treated or not treated with radiotherapy.
Gene Set Enrichment Analysis (GSEA) and survival analysis for online datasets were also performed for further validation.
Results: Among patients that received radiotherapy (82/238), those demonstrating positive SNCG expression had a 55.
0 month shorter median overall survival (OS) in comparison to those demonstrating negative SNCG expression (78.4 vs.
133.4 months, log rank χ2 = 16.13; p< 0.001). Among the patients that received no radiotherapy (156/238), SNCG status
was not correlated with OS (log rank χ2 = 2.40; p = 0.121). A COX proportional hazard analysis confirmed SNCG
as an independent predictor of OS, only for patients who have received radiotherapy. Similar results were also
obtained for distant metastasis-free survival (DMFS). A GSEA analysis indicated that SNCG was strongly associated with
genes related to a radiation stress response. A survival analysis was performed with online databases consisting of
breast cancer, lung cancer, and glioblastoma and further confirmed SNCG’s significance in predicting the survival of
patients that have received radiotherapy.
Conclusion: A positive SNCG may serve as a potential marker to identify breast cancer patients who are less likely to
benefit from radiotherapy and may also be extended to other types of cancer. However, the role of SNCG in
radiotherapy response still needs to be further validated in randomized controlled trials prior to being exploited
in clinical practice.
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Background
Breast cancer is the most frequently diagnosed cancer
among females worldwide [1]. In more developed coun-
tries like the U.S., breast cancer death rates have slowly
decreased by 1.4 % per year [2, 3]; however, in less devel-
oped areas, both of the incidence rate and mortality rate
of breast cancer are still raising [1]. In 2013, breast can-
cer accounted for 25 % of total cancer cases and 15 % of
cancer-related deaths worldwide [1]. For decades, surgi-
cal removal of the primary tumor has been the major
therapeutic option [4, 5], and the addition of adjuvant
radiotherapy based on a risk of recurrence and metasta-
sis has been found to significantly improve the overall
prognosis. Currently, adjuvant radiotherapy after mast-
ectomy has been widely accepted as the gold standard of
care for patients with tumors > 5 cm in size, 4 or more
positive lymph nodes, or positive margins [6]. However,
radiotherapy is also associated with potential long-term
side effects and radiation oncologists have to be highly
selective of patients and administer radiation treatments
with extreme caution [6, 7]. Despite such precautions,
not every patient subjected to radiotherapy can particu-
larly benefit from it. Thus, biomarkers capable of predict-
ing radiotherapeutic efficacy would largely strengthen
current clinical options by providing instructions for ap-
propriate risk evaluation and treatment plan selection.
Synuclein-γ (SNCG) was first identified as breast can-
cer–specific gene 1 (BCSG1), and was isolated from
cDNA libraries of breast carcinoma in the 1990s [8, 9].
SNCG is highly expressed in advanced and metastatic
breast tumors but not in normal breast epithelium tissues.
In breast cancer cells, SNCG protein impairs cell cycle
checkpoints [10, 11], confers chemoresistance [12, 13],
and enhances metastasis in nude mice [14]. Although the
detailed mechanism is not fully understood, SNCG’s role
in the oncogenesis-related Akt and mTOR pathways [15]
and the neural development-related PPARγ pathway [16]
are noteworthy and worth further investigation. The poor
overall SNCG-related prognosis in breast cancer has been
reported by two independent studies [17, 18]. Moreover,
SNCG was overexpressed in other cancerous tissues and
this overexpression was a prediction of poor prognosis in
several types of cancer [17–22]. Nevertheless, the relation-
ship between SNCG expression and radiotherapeutic effi-
cacy remains to be elucidated.
The aim of this study is to explore the impact of
SNCG expression on the prognosis as well as multiple
clinical manifestations of breast cancer patients treated
with radiotherapy. Surgically resected specimens from
breast cancer patients as well as expression profiling
datasets from online repositories were simultaneously
analyzed. SNCG expression and its relationship with
pathological parameters were investigated on both pro-
tein and transcript levels, and high SNCG expression
were suggested to be an indication of fewer radiothera-
peutic benefits. Furthermore, our finding was also vali-
dated by analysis performed in two online datasets of
different cancer types with radiotherapy information. In
conclusion, this study has revealed the prospective value
of SNCG expression in predicting whether breast cancer
patients could benefit from radiotherapy, and could fur-




A cohort of 454 invasive breast cancer patients that re-
ceived radical or modified radical mastectomy between
the years of 1996 and 2002 in the Breast Center at the
Peking University Cancer Hospital & Institute. The pro-
ject was approved and supervised by the research ethics
committee of Peking University Cancer Hospital & Insti-
tute. Written informed consents were obtained from all
participants. Patients with indications for postoperative
radiotherapy were recruited: patients with T3/4 tumors
(i.e. tumor size > 5 cm in size, or positive margins), pa-
tients with four or more positive lymph nodes, T1/2 pa-
tients with one to three positive nodes and other risk
factors of recurrence (i.e. ≤ 40 years old, hormone
receptor-negative, HER2 positive, incomplete lymph
node dissection or more than 20 % positive nodes). The
presence of ER and PR was evaluated using the
charcoal-dextran method. ER and PR values of more
than 10 fmol/mg were considered positive. Status of
HER2 was assessed by IHC with a rabbit polyclonal anti-
body (DAKO A0485; 1:250 dilution), and scored by the
Diagnostic Pathological Department, Peking University
Cancer Hospital. Eight fields were randomly selected in
each slide and slides were counted under a Nikon
microscope at 200× amplification [17]. Among the
454 breast cancer patient cohort, 238 of the cases
with indications for postoperative radiotherapy were
selected while only 82 of them had been treated with
radiotherapy. No patients involved in this study have
received neoadjuvant chemotherapy.
Radiotherapy treatment
Overall, there were 238 patients with indications for
postoperative radiotherapy that were selected. The se-
lected patients were aged from 25 to 81 years (median
52 years). 82 of them were typically treated with stand-
ard radiotherapy in 25 fractions (50 Gy at 2 Gy per frac-
tion, 5 fractions per week), and ensured that the
radiotherapy dose was actually delivered to the CTV
(clinical target volume) with 6 MV photons or electron
beam. The remaining 156 patients had not been sub-
jected to radiotherapy.
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Clinical samples handling
Surgically resected tissue specimens were used in this
study. Formalin fixed, paraffin-embedded breast cancer
tissue specimens from the above 238 patients were ob-
tained from the Breast Center at Peking University Cancer
Hospital & Institute. The study was approved and su-
pervised by the Medical Ethics Committee of Peking
University Cancer Hospital & Institute and each pa-
tient had given formal consent. All specimens were
taken before the onset of chemotherapy or hormonal
treatment. The total period of follow-up was 60–192
months with a median period of 127 months.
Immunohistochemical staining
Specimens were cut into 5 μm sections. After baking at
60 °C overnight, sections were dewaxed and rehydrated
through xylene and alcohol series. Antigen retrieval was
performed via microwave cooking in ethylene diamine
tetra acetic acid (pH 8.0, Zymed) for 20 min. Endogen-
ous peroxidase activity was blocked by incubation in 3 %
hydrogen peroxide for 10 min at room temperature.
Non-specific binding was blocked with 10 % goat serum.
Then slides were subjected to overnight incubation at 4 °C
with anti-SNCG monoclonal antibody generated in our la-
boratory [17]. After incubation with a biotin-conjugated
secondary anti-mouse antibody for 30 min and 3 washes
with phosphate-buffered saline with 0.1 % Tween-20,
slides were treated with diaminobenzidine (DAB) working
solution at room temperature for 3–10 min, and then
washed in distilled water and counterstained with
hematoxylin. The negative control was prepared by re-
placing the SNCG antibody with non-immune IgG in a
randomly selected breast cancer tissue slide, and the posi-
tive control was prepared with SNCG antibody in a
known SNCG positive breast cancer tissue slide which
had been proved in a previous study [17].
IHC grading system
All of the samples were independently inspected under a
light microscope (APPLIED IMAGING at 200×) by two
experienced pathologists. Both the percentage of positive
cells and the intensity of staining in 10 randomly chosen
microscopic fields were evaluated. According to our previ-
ous publications, the grading system was based on a 4-
value classification scale as follows: the area of staining was
graded as <10 % (0) or >10 % (1) of all cancer cells stained
within the section; intensity of staining was graded as none
(0), weak (1), moderate (2) or strong (3). The final grade
was obtained by adding area grade and intensity grade to-
gether, and final grade ≥ 3 was defined as positive [20, 23].
Validating analysis
EBI ArrayExpress dataset E-TABM-158 and NCBI GEO
dataset GSE1456 are two online breast cancer datasets
with radiotherapy information [24, 25]. Both of the
two datasets with their supplementary clinical infor-
mation were downloaded and used for validating ana-
lysis. A pearson correlation analysis was performed to
assess the gene-gene expression correlation. A hierarchical
clustering was used to distinguish different subgroups ac-
cording to expression level of given genes. Gene Set En-
richment Analysis (GSEA) was performed to evaluate
correlation between SNCG expression and two radiation
stress response gene sets [26, 27]. Lung cancer dataset
CaArray and glioblastoma dataset GSE13041 with radio-
therapy information were also downloaded and used for
validating analysis [28–30].
Statistical analysis
Since the populations of stage II patients in the radio-
therapy subgroup were too small to perform a separate
multivariate analysis, we combined the samples in stage
II and III to make it sufficient for statistics. All statistical
analyses were performed using the R 3.1.2 software
(www.r-project.org). Correlations that were made be-
tween the SNCG expression and clinicopathologic char-
acteristics were tested by the Pearson χ2 test. The
Kaplan-Meier curve was used to evaluate overall survival
(OS) and distant metastasis-free survival (DMFS) rates,
and differences were tested by log-rank test. The COX
proportional hazard model was used for multivariate
analysis. Hazard ratios (HR) and 95 % confidence
interval (CI) were calculated. All statistical analyses
were 2-sided, and a p value less than 0.05 were con-
sidered statistically significant. For false discovery rate
(FDR) analysis, a cutoff of 0.25 was selected according
to GSEA’s suggestion [26].
Results
Association of SNCG expression and clinicopathologic
features
IHC staining of SNCG was performed for all samples.
According to our grading criteria, 139 samples among
238 were defined as SNCG negative while another 99
were defined as SNCG positive (total positive rate =
41.6 %). Representative images of SNCG staining in
breast cancer tissues with examples of scoring were
shown in Fig. 1. Positive rates of SNCG were 41.5 %
(34/82) in patients that received radiotherapy and
41.7 % (65/156) in those that did not receive radio-
therapy, and there was no significant difference (χ2 =
0.001, p = 0.976). For patients treated with radiother-
apy or not, there were no significant associations
between SNCG expression and Age (p = 0.767, 0.665),
Tumor size (p = 0.145, 0.142), Metastasis lymph node
(p = 0.117, 0.332), TNM stage (p = 0.428, 0.957), ER
status (p = 0.304, 0.998), PR status (p = 0.171, 0.904),
or HER2 status (p = 0.351, 0.646), and all of the
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clinicopathologic features in both subgroups were
equally distributed (Table 1).
Relationship between SNCG expression and radiotherapy
stratified survival
Positive SNCG was correlated with decreased OS
(median OS: 108.3 vs. 144.6 months; log rank χ2 =
13.45; p < 0.001; Fig. 2a) and DMFS (median DMFS:
81.2 vs. 127.7 months; log rank χ2 = 17.83; p < 0.001;
Fig. 2d) in breast cancer patients, regardless of the
utilization or non-utilization of radiotherapy.
Among patients that received radiotherapy, those with
positive SNCG expression had a 55.0 months shorter
median OS than those with negative SNCG expression
(median OS: 78.4 vs. 133.4 months; log rank χ2 = 16.13;
p < 0.001; Fig. 2b). However, among patients that were
not subjected to radiotherapy, there was no significant
difference between OS of patients with positive SNCG
expression and those with negative SNCG expression
(median OS: 122.4 vs. 143.1 months; log rank χ2 = 2.40;
p = 0.121; Fig. 2c). Similar results were also obtained
for DMFS (for patients received radiotherapy, median
DMFS: 52.9 vs. 116.7 months, Fig. 2e; for patients did
not receive radiotherapy, median DMFS: 95.1 vs.
126.7 months, Fig. 2f ).
Univariate and multivariate analysis for the radiotherapy
stratified prognosis
In univariate analysis, tumor size, lymph nodes metasta-
sis, TNM stage, SNCG expression were statistically asso-
ciated with OS in patients that received radiotherapy,
while lymph nodes metastasis, TNM stage, and HER2
status were prognostic factors of OS in patients that did
not receive radiotherapy (Table 2).
Multivariate analyses using COX regression analysis
identified TNM stage (Wald χ2 = 10.31; p = 0.001) and
SNCG (Wald χ2 = 6.62; p = 0.010) expression, which
were both independent predictors of OS in patients that
received radiotherapy. However, in patients that did not
receive radiotherapy, only TNM stage (Wald χ2 = 7.32;
p = 0.007) remained an independent prognostic factor
(Table 3). Similar results were also obtained for
DMFS (Additional file 1: Table S1 and S2). Taken together,
SNCG expression affected the survival of breast cancer
patients to a greater extent in patients that received
radiotherapy.
Association between SNCG expression and radiation
stress response gene sets
SMIRNOV_RESPONSE_TO_IR_2HR_DN gene set in-
cludes a series of genes that are down-regulated in
Fig. 1 Representative immunohistochemical staining for SNCG expression in breast cancer tissues. a 100 × and b 200 × staining of negative
sample 1 (area grade 0, intensity grade 0); c 100 × and d 200 × staining of negative sample 2 (area grade 1, intensity grade 1); e 100 × and f
200 × staining of positive sample (area grade 1, intensity grade 3); g Staining of negative control (100×); h Staining of positive control (100×)
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Table 1 Association of SNCG expression with clinicopathological parameters in breast cancer patients were or were not treated
with radiotherapy
Characteristics Radiotherapy No Radiotherapy
SNCG- SNCG+ χ2 p-value SNCG- SNCG+ χ2 p-value
Age 0.088 0.767 0.188 0.665
<50 years 21 16 43 33
≥50 years 27 18 48 32
Tumor size 2.126 0.145 2.161 0.142
<2 cm 29 15 40 21
≥2 cm 19 19 51 44
Metastasis lymph node 4.393a 0.117 2.202 0.332
0 19 7 34 17
1–3 6 3 31 27
≥4 23 24 26 21
TNM stage 0.628 0.428 0.003a 0.957
I 12 6 7 4
II, III 36 28 84 61
ER 1.058 0.304 0.001 0.998
negative 12 13 34 25
positive 32 21 53 39
PR 1.874 0.171 0.014 0.904
negative 23 23 44 33
positive 21 11 43 31
HER2 0.871 0.351 0.211 0.646
negative 28 21 50 41
positive 7 9 14 14
aChi-square test with Yates’ continuity correction
Fig. 2 Kaplan-Meier curve of OS/DMFS in breast cancer patients evaluated according to SNCG expression, stratified with radiotherapy reception.
All patients (a, d); patients received radiotherapy (b, e); patients did not receive radiotherapy (c, f)
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lymphocytes at 2 h after exposure to 10 Gy dose of ion-
izing radiation [31] and MAYBURD_RESPONSE_-
TO_L663536_DN gene set includes a series of genes
down-regulated in cancer cells after treatment with
L663536, a small molecular chemical found to enhance
the effect of radiation in cancer cells [32]. These two
gene sets located in the Molecular Signatures Database
(MSigDB) were downloaded to perform GSEA analysis
in online datasets E-TABM-158 and GSE1456.
In ArrayExpress dataset E-TABM-158, the Normalized
Enrichment Score (NES) of MAYBURD_RESPONSE_TO_
L663536_DN gene set was −1.571 (p = 0.049, FDR = 0.238,
Fig. 3a), indicating SNCG expression is negatively cor-
related with genes in this gene set significantly. For
SMIRNOV_RESPONSE_TO_IR_2HR_DN gene set, a
NES of −1.532 was achieved (p = 0.036, FDR = 0.236,
Fig. 3b).
Similar results were also obtained in the NCBI GEO
dataset GSE1456. NES of MAYBURD_RESPONSE_-
TO_L663536_DN was −1.667 (p = 0.025, FDR = 0.137,
Fig. 3c), while NES of MIRNOV_RESPONSE_TO_IR_2
HR_DN was −1.569 (p = 0.028, FDR = 0.196, Fig. 3d).
Relationship between SNCG expression and radiotherapy
stratified survival in validating dataset
A validating survival analysis was then conducted. Con-
sidering that the sample size of GSE1456 was too small
to stratify, only the E-TABM-158 dataset was used in the
subsequent survival analyses. The E-TABM-158 dataset
was stratified to the radiotherapy subgroup and the non-
radiotherapy subgroup.
In the radiotherapy subgroup, patients with high SNCG
levels had a worse DMFS values than those with low
SNCG levels. A suggestive p-value was achieved, consider-
ing the small sample size (Fig. 3e, log-rank χ2 = 2.45, p =
0.118). In the non-radiotherapy subgroup, patients with
different SNCG levels had nearly the same survival out-
come (Fig. 3f, log-rank χ2 = 0.35, p = 0.555). Addition-
ally, the percentage of censored data was too high to
calculate the median DMFS in both subgroups.
To get a survival indicator of higher resolution, a set
of SNCG correlated genes (the expression of those genes
was correlated with SNCG in both E-TABM-158 and
GSE1456 datasets) were recruited to construct a novel
SNCG signature. In the radiotherapy subgroup, patients
with different SNCG signatures showed a significant
Table 2 Prognostic factors of OS in univariate analysis of breast cancer patients were or were not treated with radiotherapy
Characteristics Radiotherapy No Radiotherapy
RR (95 % CI) p-value RR (95 % CI) p-value
Age 0.429 0.739
≥50 vs. <50 0.759 (0.383, 1.503) 1.098 (0.635, 1.898)
Tumor size 0.011 0.730
≥2 cm vs. <2 cm 2.432 (1.203, 4.918) 1.104 (0.628, 1.944)
Metastasis lymph node <0.001 0.001
1-3 vs. 0 1.878 (0.314, 11.243) 0.935 (0.433, 2.017)
≥4 vs. 0 8.151 (2.475, 26.845) 2.763 (1.415, 5.396)
TNM stage <0.001 <0.001
II, III vs. I 6.624 (2.556, 17.171) 2.906 (1.681, 5.025)
SNCG <0.001 0.126
Positive vs. Negative 4.058 (1.929, 8.537) 1.530 (0.888, 2.638)
ER 0.176 0.183
Positive vs. Negative 0.613 (0.306, 1.226) 1.530 (0.818, 2.861)
PR 0.485 0.232
Positive vs. Negative 0.782 (0.391, 1.561) 1.423 (0.798, 2.538)
HER2 0.985 0.018
Positive vs. Negative 1.008 (0.434, 2.341) 2.304 (1.152, 4.606)
RR Risk Ratio, CI confidence interval
Table 3 Independent predictors of OS in multivariate analysis of
breast cancer patients were or were not treated with radiotherapy
Characteristics Radiotherapy No Radiotherapy
RR (95 % CI) p-value RR (95 % CI) p-value
TNM stage 0.001 0.007
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difference in DMFS (log-rank χ2 = 3.87, p = 0.049, Fig. 4a,
b), while in the non-radiotherapy subgroup, patients with
different SNCG signatures had similar DMFS (log-rank
χ2 = 1.16, p = 0.282, Fig. 4c, d).
Relationship between SNCG expression and radiotherapy
stratified survival in other types of cancer
Additionally, a relationship between SNCG expression
and radiotherapy-related survival was further testified in
other cancers. Pertaining to the lung cancer dataset
CaArray, high SNCG levels indicated a significantly
worse OS than low SNCG level in patients that received
radiotherapy (median OS: 25.5 vs. 44.4 months; log rank
χ2 = 4.64; p = 0.030; Fig. 5a, c). Similar OS was observed
regardless of the SNCG level in patients that did not re-
ceive radiotherapy (median OS: 75.7 vs. 79.5 months; log
rank χ2 = 0.14; p = 0.711; Fig. 5b, d).
Regarding the glioblastoma dataset GSE13041, a high
SNCG level indicated a marginally significantly worse
OS than low SNCG level in patients received radiother-
apy (median OS: 6.0 vs. 11.5 months; log rank χ2 = 3.61;
p = 0.050; Fig. 5e, g). In patients that did not receive
radiotherapy, a similar OS was observed regardless of
the SNCG level (median OS: 14.5 vs. 14.0 months; log
rank χ2 = 0.17; p = 0.678; Fig. 5f, h).
Discussion
Despite that the overexpression of SNCG has long been
observed in cancers and high levels of SNCG expression
has been validated to be associated with poorer OS and
DMFS in multiple types of cancer, the suitability of
SNCG expression as a biomarker for patient selection in
radiotherapy remains largely unknown [17–21]. Kang
et al. reported that radiotherapy induced SNCG expres-
sion in the MCF7 cell line, which may contribute to im-
mune suppressive effects by inhibiting the differentiation
and activation of dendritic cells. Yet the linkage between
SNCG and radiotherapy remains to be elucidated [33].
Fig. 3 SNCG expression is associated with radiation related GSEA gene sets and radiotherapy related survival. Normalized Enrichment Score (NES)
of MAYBURD_RESPONSE_TO_L663536_DN gene set in breast cancer dataset E-TABM-158 (a) and GSE1456 (c); Normalized Enrichment Score (NES)
of SMIRNOV_RESPONSE_TO_IR_2HR_DN gene set in breast cancer dataset E-TABM-158 (b) and GSE1456 (d); Kaplan-Meier curve of DMFS evaluated
according to SNCG expression in patients received radiotherapy (e) and patients did not receive radiotherapy (f) in breast cancer dataset E-TABM-158
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In this study, to reveal the association between SNCG ex-
pression and the radiotherapeutic response, we performed
a retrospective analysis in which 238 of 454 breast cancer
patients were selected according to the indications for
postoperative radiotherapy. The aim of this case-by-case
screening was to reduce the heterogeneity of our study
cohort. In both subgroups stratified with radiotherapy
reception, no clinicopathologic feature was found to be
associated with SNCG expression, indicating that our pa-
tients’ data from different subgroups were comparable.
Meanwhile, none of our selected patients have received
neoadjuvant chemotherapy, which we believe can
minimize the pre-surgical bias between groups of patients.
Overall, patients with positive SNCG expression status
showed a significantly worse prognosis than patients with
negative SNCG expression, which is consistent with the
results of previous reports [17, 18].
Detailed analysis has revealed that among patients that
have received radiotherapy, the diversity of prognosis be-
tween the SNCG positive and the SNCG negative groups
was significantly expanded among patients without radio-
therapy treatment. The negative impact of SNCG on prog-
nosis were twice higher for radiotherapy treated patients
than for those who did not receive radiotherapy (medium
diversity of OS: −55.0 vs. -20.7 months; medium diversity
of DMFS: −63.8 vs. -31.6 months), indicating SNCG is
indeed associated with radiotherapeutic efficacy. A COX
regression analyses was performed to rule out possible
confounding factors. SNCG expression was identified
as an independent predictor of OS in patients that re-
ceived radiotherapy, but not in those that received no
radiotherapy. The same analysis was also conducted
only for patients of stage III and SNCG was again
found to be associated with radiotherapy efficacy (data
not shown). Taken together, we hypothesize that posi-
tive SNCG may indicate a lack of benefit from radio-
therapy for breast cancer patients.
To test whether SNCG expression was correlated with
cell response to radiation, two radiation stress related gene
sets (SMIRNOV_RESPONSE_TO_IR_2HR_DN [31] and
MAYBURD_RESPONSE_TO_L663536_DN [32]) were
simultaneously used for gene set enrichment analysis
(GSEA) in online breast cancer datasets E-TABM-158 and
GSE1456. In both datasets, SNCG expression is negatively
enriched with both gene sets, indicating that SNCG was
highly correlated with radiation stress. To further eluci-
date SNCG’s association with radiotherapy, the online
dataset E-TABM-158 was used for stratified survival ana-
lysis. In the radiotherapy subgroup, a high-SNCG expres-
sion was suggested to be related with adverse DMFS
despite that the statistic was not significant. SNCG and
SNCG-correlated genes were recruited to build a
Fig. 4 Relationship between expressions of SNCG correlated genes and radiotherapy stratified survival in validating dataset. Hierarchical clustering
result of patients received radiotherapy (a) and patients did not receive radiotherapy (c) in breast cancer dataset E-TABM-158 by SNCG-correlated
genes; Kaplan-Meier curve of DMFS in patients received radiotherapy (b) and patients did not receive radiotherapy (d), grouped by clustering
result of SNCG-correlated genes, in breast cancer dataset E-TABM-158
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signature, and signature related prognosis was ob-
served. In contrast, in the non-radiotherapy subgroup,
prognosis showed no difference whether grouped by a
SNCG or a SNCG-correlated signature. The results
presented here strongly support that positive SNCG
may serve as a potential biomarker to identify breast
cancer patients who are less likely to benefit from
radiotherapy.
Fig. 5 SNCG expression is associated with radiotherapy related survival in other types of cancer. Kaplan-Meier curve of OS in patients received
radiotherapy (a) and patients did not receive radiotherapy (b) in lung cancer dataset CaArray; Mortal rate of patients received radiotherapy (c) and
patients did not receive radiotherapy (d) in lung cancer dataset CaArray; Kaplan-Meier curve of OS in patients received radiotherapy (e)
and patients did not receive radiotherapy (f) in glioblastoma dataset GSE13041; Mortal rate of patients received radiotherapy (g) and patients did not
receive radiotherapy (h) in glioblastoma dataset GSE13041
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How SNCG expression affects sensitivity to radiother-
apy still remains unclear. In breast cancer cells, SNCG
interacts with phospholipase Cβ2 to modulate G protein
activation [34] and it also has the potential to stimulate
the ER pathway [35], which may increase cell malig-
nancy. Additionally, SNCG confers resistance to anti-
microtubule agents by forming a complex with BubR1
[11, 12, 36]. Considering that the main mechanism of
radiotherapy is DNA damage-induced cell cycle arrest
and growth inhibition [37], interaction between SNCG
and BubR1 may partially explain the role of SNCG in
breast cancer cells’ response to radiation. Given that radi-
ation could also kill cancer cells effectively through facili-
tating Reactive Oxygen Species (ROS) generation [38], the
possible association between SNCG and ROS-regulated
signaling pathway is worth further investigation.
We also explored the possibility that SNCG may serve
as a radiotherapy-related biomarker in other types of
cancer. The lung cancer dataset CaArray and the glio-
blastoma dataset GSE13041 were recruited and results
similar to breast cancer were achieved, suggesting that
SNCG’s role in identifying cancer patients less likely to
benefit from radiotherapy may be universal in various
types of cancer. To make this suggestion stronger, data-
sets with enough radiotherapy information of more can-
cer types were needed.
Conclusion
This is the first study that demonstrates that SNCG could
potentially be used as a biomarker to predict a worse patient
outcome and less patient benefit as a consequence of radio-
therapy for breast cancer. This study also raises an import-
ant issue regarding the postoperative adjuvant management
of breast cancer. We truly believe that this is an important
analysis since patients who have recently undergone a mast-
ectomy and have begun receiving radiotherapy will derive
the most benefit from the appropriate risk evaluation and
treatment plan selection. Furthermore, an early prediction
of radiotherapy treatment efficacy could also potentially im-
prove their quality of life. Considering our results were ob-
tained from a retrospective study, confirmative studies with
other cohorts or by prospective, randomly controlled, and
double-blinded studies were required.
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